340 related articles for article (PubMed ID: 7493612)
1. The selective angiotensin AT1 receptor antagonist LR-B/081 potently inhibits drinking induced by central injection of angiotensin II in rats.
Polidori C; Ciccocioppo R; Pompei P; Cirillo R; Massi M
Eur J Pharmacol; 1995 Apr; 277(2-3):223-8. PubMed ID: 7493612
[TBL] [Abstract][Full Text] [Related]
2. Functional evidence for the ability of angiotensin AT1 receptor antagonists to cross the blood-brain barrier in rats.
Polidori C; Ciccocioppo R; Pompei P; Cirillo R; Massi M
Eur J Pharmacol; 1996 Jul; 307(3):259-67. PubMed ID: 8836613
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II-induced responses in vascular smooth muscle cells: inhibition by non-peptide receptor antagonists.
Catalioto RM; Porchia R; Renzetti AR; Criscuoli M; Subissi A; Giachetti A
Eur J Pharmacol; 1995 Jul; 280(3):285-92. PubMed ID: 8566096
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of LR-B/081, a new highly potent, selective and orally active, nonpeptide angiotensin II AT1 receptor antagonist.
Cirillo R; Renzetti AR; Cucchi P; Guelfi M; Salimbeni A; Caliari S; Castellucci A; Evangelista S; Subissi A; Giachetti A
Br J Pharmacol; 1995 Mar; 114(6):1117-24. PubMed ID: 7620700
[TBL] [Abstract][Full Text] [Related]
5. Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats.
Culman J; von Heyer C; Piepenburg B; Rascher W; Unger T
Eur J Pharmacol; 1999 Feb; 367(2-3):255-65. PubMed ID: 10079000
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin AT1 receptor-mediated vasopressin release and drinking are potentiated by an AT2 receptor antagonist.
Höhle S; Spitznagel H; Rascher W; Culman J; Unger T
Eur J Pharmacol; 1995 Mar; 275(3):277-82. PubMed ID: 7768295
[TBL] [Abstract][Full Text] [Related]
7. The role of angiotensin, AT1 and AT2 receptors in the pressor, drinking and vasopressin responses to central angiotensin.
Hogarty DC; Speakman EA; Puig V; Phillips MI
Brain Res; 1992 Jul; 586(2):289-94. PubMed ID: 1521162
[TBL] [Abstract][Full Text] [Related]
8. Drinking induced by subcutaneous injection of angiotensin II in the rat is blocked by the selective AT1 receptor antagonist DuP 753 but not by the selective AT2 receptor antagonist WL 19.
Dourish CT; Duggan JA; Banks RJ
Eur J Pharmacol; 1992 Jan; 211(1):113-6. PubMed ID: 1618259
[TBL] [Abstract][Full Text] [Related]
9. Intravenous losartan inhibits the increase in plasma luteinizing hormone and water intake produced by intraventricular angiotensin II.
Palmer AA; Steele MK; Shackelford RL; Ganong WF
Proc Soc Exp Biol Med; 1994 Mar; 205(3):263-6. PubMed ID: 8171048
[TBL] [Abstract][Full Text] [Related]
10. Effect of Losartan, a nonpeptide angiotensin II receptor antagonist, on drinking behavior and renal actions of centrally administered renin.
Barbella Y; Cierco M; Israel A
Proc Soc Exp Biol Med; 1993 Apr; 202(4):401-6. PubMed ID: 8456103
[TBL] [Abstract][Full Text] [Related]
11. In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist.
Siegl PK; Chang RS; Mantlo NB; Chakravarty PK; Ondeyka DL; Greenlee WJ; Patchett AA; Sweet CS; Lotti VJ
J Pharmacol Exp Ther; 1992 Jul; 262(1):139-44. PubMed ID: 1625193
[TBL] [Abstract][Full Text] [Related]
12. BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174.
Dickinson KE; Cohen RB; Skwish S; Delaney CL; Serafino RP; Poss MA; Gu Z; Ryono DE; Moreland S; Powell JR
Br J Pharmacol; 1994 Sep; 113(1):179-89. PubMed ID: 7812609
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models.
Lacour C; Canals F; Galindo G; Cazaubon C; Segondy D; Nisato D
Eur J Pharmacol; 1994 Nov; 264(3):307-16. PubMed ID: 7698170
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the ability of irbesartan to cross the blood-brain barrier following acute intragastric treatment.
Polidori C; Ciccocioppo R; Nisato D; Cazaubon C; Massi M
Eur J Pharmacol; 1998 Jul; 352(1):15-21. PubMed ID: 9718262
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).
Shibouta Y; Inada Y; Ojima M; Wada T; Noda M; Sanada T; Kubo K; Kohara Y; Naka T; Nishikawa K
J Pharmacol Exp Ther; 1993 Jul; 266(1):114-20. PubMed ID: 8331552
[TBL] [Abstract][Full Text] [Related]
16. Effect of a non-peptide angiotensin receptor antagonist on water intake caused by centrally administered carbachol in the rat.
Reis LC; Saad WA; Camargo LA; Renzi A; Menani JV
Braz J Med Biol Res; 1996 Feb; 29(2):245-7. PubMed ID: 8731356
[TBL] [Abstract][Full Text] [Related]
17. In vivo pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist.
Cazes M; Provost D; Versigny A; Cloarec A
Eur J Pharmacol; 1995 Sep; 284(1-2):157-70. PubMed ID: 8549620
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of YM358, a novel nonpeptide angiotensin AT1 receptor antagonist.
Shibasaki M; Fujimori A; Takanashi M; Kusayama T; Tokioka T; Satoh Y; Okazaki T; Uchida W; Inagaki O; Yanagisawa I
Eur J Pharmacol; 1997 Sep; 335(2-3):167-73. PubMed ID: 9369370
[TBL] [Abstract][Full Text] [Related]
19. Lack of a centrally-mediated antihypertensive effect following acute or chronic central treatment with AT1-receptor antagonists in spontaneously hypertensive rats.
Bunting MW; Widdop RE
Br J Pharmacol; 1995 Dec; 116(8):3181-90. PubMed ID: 8719794
[TBL] [Abstract][Full Text] [Related]
20. Functional interaction between losartan and central tachykinin NK3 receptors in the conscious rat.
Picard P; Chrétien L; Couture R
Br J Pharmacol; 1995 Apr; 114(8):1563-70. PubMed ID: 7541280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
